Literature DB >> 19372037

The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use.

Stephanie C Manson1, Ruth E Brown, Annamaria Cerulli, Carlos Fernandez Vidaurre.   

Abstract

Oral corticosteroids (OCS) are a key part of therapy regimens for a diverse variety of conditions. Despite their efficacy, they are associated with a wide variety of adverse events. The purpose of this review was to identify the range of adverse events that have been reported to be related to oral corticosteroids, examine the factors that influence their incidence and estimate the economic burden caused by these adverse events. In 61 identified studies, 21 different categories of OCS related adverse events were reported with increased fracture risk being the category most frequently described. Most studies that examined factors linked to the incidence of OCS related adverse events found that dose, age, gender, duration of use, treatment history, smoking habits or cholesterol level were influential in determining risk. Additionally, a cumulative economic analysis of selected adverse events found the annual cost of treating these events in the UK to be at least 165 pounds per patient taking OCS. The clinical and economic burden of OCS related adverse events highlights the need for OCS sparing therapies to be developed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372037     DOI: 10.1016/j.rmed.2009.01.003

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  62 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Vinpocetine as a potent antiinflammatory agent.

Authors:  Alexandre E Medina
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-21       Impact factor: 11.205

3.  PURLs: corticosteroids for a sore throat?

Authors:  Keri Bergeson; Nina Rogers; Shailendra Prasad
Journal:  J Fam Pract       Date:  2013-07       Impact factor: 0.493

4.  Things We Do for No Reason: Systemic Corticosteroids for Wheezing in Preschool-Aged Children.

Authors:  Yemisi O Jones; Brittany B Hubbell; Joanna Thomson; Jennifer K O'Toole
Journal:  J Hosp Med       Date:  2019-07-24       Impact factor: 2.960

5.  Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism.

Authors:  Kye-Im Jeon; Xiangbin Xu; Toru Aizawa; Jae Hyang Lim; Hirofumi Jono; Dong-Seok Kwon; Jun-Ichi Abe; Bradford C Berk; Jian-Dong Li; Chen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-06       Impact factor: 11.205

6.  Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.

Authors:  S Kabadi; J Yeaw; A K Bacani; E Tafesse; K Bos; S Karkare; M DeKoven; E R Vina
Journal:  Lupus       Date:  2018-08-01       Impact factor: 2.911

7.  Secondary Antibody Deficiency in Glucocorticoid Therapy Clearly Differs from Primary Antibody Deficiency.

Authors:  Clemens Wirsum; Cornelia Glaser; Sylvia Gutenberger; Baerbel Keller; Susanne Unger; Reinhard E Voll; Werner Vach; Thomas Ness; Klaus Warnatz
Journal:  J Clin Immunol       Date:  2016-03-15       Impact factor: 8.317

8.  Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.

Authors:  Pauline Lancia; Beate Aurich; Phuong Ha; Anne Maisin; Véronique Baudouin; Evelyne Jacqz-Aigrain
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

9.  The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic.

Authors:  Terri S Armstrong; Yuan Ying; Jimin Wu; Alvina A Acquaye; Elizabeth Vera-Bolanos; Mark R Gilbert; Paul D Brown; Janette Vardy; Caroline Chung
Journal:  Neuro Oncol       Date:  2015-04-09       Impact factor: 12.300

Review 10.  Corticosteroid-use in primary and secondary brain tumour patients: a review.

Authors:  Richella Ryan; Sara Booth; Stephen Price
Journal:  J Neurooncol       Date:  2011-10-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.